Answers are grounded in this paper and cite their sources.
There is a critical need for evidence-based guidelines and randomized trials to manage bleeding complications in patients treated with target-specific oral anticoagulants.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yates et al. (2013) conducted a review in Thromboembolic disorders and bleeding complications. Target-specific oral anticoagulants (TSOAs) vs. Warfarin was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: